Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...

Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the...

CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...

CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...